For two decades the unwritten rule of the American biotech IPO was that you needed an address in Cambridge or South San Francisco to be taken seriously by the funds that price the deal. That rule is gone. In 2025 only 11 drug developers went public in the United States, raising about $1.6 billion between them, the lowest count in years. By the second quarter of 2026 the window had reopened: Kailera Therapeutics raised $625 million in April and Parabilis Medicines $670 million in June, each a single deal worth more than a third of everything the class of 2025 had raised together. None of that money cares where the founders sit.
What changed is the geography, not the procedure. In the first quarter of 2026 Agomab Therapeutics, headquartered in Antwerp, raised $200 million on Nasdaq, the only European biotech to float in America that quarter. In May, Hemab Therapeutics, run out of Copenhagen and Cambridge, raised $346.7 million. A year earlier Ascentage Pharma had carried its Hong Kong listing onto Nasdaq for $126.4 million, the first company under that exchange's Chapter 18A regime to do so. None of them built a Boston headquarters to qualify. What each did instead was clear a procedural bar that has not moved an inch: the funds that price an American deal still want an anchor book, a clean corporate structure and a clinical story they can underwrite. As Ben Zercher of PitchBook put it in June 2026, the public markets are rewarding "clinically-driven asset-specific stories," wherever the issuer is based.
Three doors, not one
There are three ways into American public capital without an American office, and they are not interchangeable. The first is the crossover-to-IPO: a late private round seeded with public-market investors, followed by a Nasdaq or NYSE listing 6-18 months later. It is the cleanest path and the one the funds prefer, because it lets them build conviction before they are asked to price. The second is the PIPE-into-reverse-merger: the company folds into a listed shell and raises a private placement at the same moment, inheriting a ticker without a roadshow. It is faster and more certain, and it carries the most legal and tax complexity. The third is the direct US listing, with no US crossover at all, usually carried by a prior listing on another exchange that has already done the validation work. Ascentage used Hong Kong this way; ArriVent BioPharma, incorporated in Pennsylvania but built on a Chinese-licensed asset, simply priced a conventional IPO in January 2024 and raised $175 million. Which door to choose turns on three things: how much validation you already carry, how much time you have and how much disclosure you can stomach.
The crossover round: the biotech IPO's real starting line
The crossover is where most successful foreign listings actually begin, and the pool of money behind it has never been deeper. Stifel's Biotech Buyside Study, updated on May 28th 2026, counts 237 specialist life-sciences funds holding $464 billion of biotech assets, a figure that has more than tripled since 2018. Of those funds, 50 joined nine or more PIPE or registered-direct deals over the prior 40 months; RA Capital alone did 53, Janus Henderson and Adage 43 apiece. This is the institutional base a crossover round taps, and the point of the round is not the cash. It is the signal: when RA Capital or Novo Holdings takes a late private position, the IPO book is half-built before the roadshow starts. Agomab is the clearest example. Andera Partners led its Series A in 2019 and stayed in through the Nasdaq float seven years later, an anchor the American funds could read. Hemab carried Novo Holdings from seed to Series C and onto the COAG ticker. Locust Walk, which advises on these rounds, defines a crossover as venture financing with heavy participation from investors who normally buy IPOs, "usually within the 12 months prior"; in practice the well-prepared price within 3-6 months.
The reverse merger: faster, and trickier
When the IPO window is uncertain, the reverse merger buys certainty. Cooley's Carlos Ramirez and Rama Padmanabhan wrote in April 2026 that a reverse merger "can be completed in as little as 4-6 months," and that once definitive agreements are signed "the path to becoming a public company is largely locked in." The sharpest recent example is Candid Therapeutics, which announced a merger into Rallybio in early 2026 alongside a $505 million private placement from RA Capital, Venrock, Janus Henderson, T. Rowe Price and others, with Candid's own holders set to own 96.3% of the combined company. The complications cluster in three places. First, shell selection: a "fallen angel" biotech shell can be treated by the SEC as a shell company under Rule 12b-2, which delays S-3 eligibility for 12 months and stamps the issuer "ineligible" for three years. Second, the listing bar: the combined entity must clear Nasdaq's standards, either through a firm-commitment raise of at least $40 million or a year-long seasoning path. Third, and most often missed by foreign CFOs, the tax trap: Section 7874 treats the foreign parent as a US corporation for tax purposes if legacy US shareholders end up owning 80% or more, quietly erasing the reason to be offshore at all.
The direct listing, and the dual-listing hedge
The third door suits companies that already carry validation from another market. Ascentage Pharma walked its Hong Kong listing straight onto Nasdaq in January 2025, the first Chapter 18A company to dual-list in America, and used the HKEx float in place of a US crossover. Telix Pharmaceuticals did the gentler version in November 2024, adding Nasdaq ADSs while keeping its primary listing in Australia and issuing no new shares. The structural choice underneath all of this is jurisdiction. A Cayman holding company preserves foreign-private-issuer status, with its lighter 20-F reporting, but it now draws scrutiny: in October 2025 the SEC suspended trading in nine foreign companies, six of them Cayman-incorporated, and launched a Cross-Border Task Force aimed squarely at offshore issuers and their auditors. A Delaware holdco, the route Hemab took weeks before its S-1, surrenders that lighter regime and accepts full domestic reporting, but it reads as familiar to American investors. The de-SPAC remains an option, and is generally cleaner than reversing into an over-the-counter shell, but the direct listing works best for the later-stage company with a near-term readout. As Baker McKenzie's Adam Farlow noted in June 2026, the issuers getting through have been "reasonably later-stage companies with near-term readouts or excellent clinical data."
The 18-month sequence most CFOs misorder
The paths differ, but the sequencing under them is roughly fixed, and it is the sequencing that foreign CFOs most often get wrong. The arc runs about 18 months. In months 0-3 the crossover round closes and the first US institutional money comes in. In months 3-6 the company reorganizes into its Delaware or Cayman holdco and retains US counsel and a Big Four auditor under PCAOB standards, work that takes longer than anyone budgets. Months 6-9 are for drafting the S-1, holding the organizational meeting with the underwriting syndicate and preparing the testing-the-waters deck. In months 9-12 the S-1 goes to the SEC as a confidential submission, available to emerging-growth companies, and the comment cycle runs. Months 12-15 bring effectiveness and the roadshow; months 15-18, pricing and the 180-day lock-up. The common error is to invert the first two steps: foreign CFOs incorporate the offshore structure and file before they have secured the anchor book, then find the funds will not price a company they were never courted into. The fix is the one that anchors the cross-border outlicensing deals in the 2026 APAC outlicensing playbook: source the relationships years before you need them, so the crossover is a formality, not a cold call.
When staying home is the right answer
None of this means an American listing is always the answer. Hong Kong has built a real alternative: 84 companies have listed under Chapter 18A since 2018, raising more than $17.5 billion and making HKEx the second-largest biotech fundraising venue in the world, and in May 2025 the exchange opened a dedicated Technology Enterprises Channel to speed the queue. Australia's ASX offers lower listing costs and a captive buyer in the country's compulsory superannuation pool, the fifth-largest pension system on earth; Telix kept its primary listing there for a reason. Korea's KOSDAQ, quiet through the drought, showed signs of a rebound in June 2026. The test is simple: if you do not need American capital this cycle, the compliance bill and the volatility of a US listing are a cost without a return. Agomab weighed Euronext and chose Nasdaq; a Hong Kong oncology company with an HKEx book already behind it may rationally choose the reverse.
The operator's playbook: seven moves
Seven moves separate the foreign biotechs that price from the ones that wait.
One. Pick the door before the round, not after. Crossover-to-IPO if you have time and a clean story; reverse merger if you need certainty; direct listing only if another exchange has already validated you.
Two. Build the anchor book first. Court one or two of the 237 specialist funds 12-18 months ahead. RA Capital, Janus Henderson, Adage and Novo Holdings price more deals than anyone; their names on a crossover do the underwriting for you.
Three. Choose the holdco with the disclosure bill in mind. Cayman buys lighter reporting and heavier SEC scrutiny; Delaware buys the opposite. Decide which trade you can live with before you reorganize, not after.
Four. Model Section 7874 before you sign a reverse merger. If legacy US holders clear 80%, the offshore structure is dead weight and the tax benefit is gone.
Five. Retain US counsel and a PCAOB auditor in month three, not month nine. The accounting conversion is the most underbudgeted line in the sequence.
Six. Keep the home listing as a hedge. A dual listing, run the way Telix and Ascentage ran it, gives you American capital without surrendering your domestic book.
Seven. Sequence, do not rush. The CFOs who file before the book is built are the ones who pull the deal.
The bear case is the compliance bill. It is also incomplete.
The risks are real. An American listing means full SEC reporting, or the eroding shelter of foreign-private-issuer status; a Cross-Border Task Force now reading offshore audits closely; and the memory that the class of 2024 traded down roughly 50% from its IPO price within a year. For a company that does not need the money, that is a bad trade.
Telix is the counter-example. In November 2024 it added a Nasdaq line without issuing a share, without leaving Melbourne and without renting a Boston office, and reached the deepest pool of biotech capital in the world on its own terms. Access and presence have decoupled. The address on the door stopped mattering; the sequence behind it never did.